At the conclusion of this session, participants should better understand digital trends seen within Medical Affairs today as well as be aware of why HCP expectations are changing and how to evolve with them to provide better customer experiences
Evaluate the commonalities and differences in the use, structure and evolution of scientific communications platforms within and between companies; understand how a HealthScience approach can help to integrate insights, communications and evidence generation plans across multiple functions
The MAPS Medical Affairs Strategic Planning Guide and Template has been developed to provide guidance and recommendations to selected components that comprise the strategic medical affairs planning for a product – including the situational analysis, medical strategy, tactical/operational planning, and medical plan summary.
This MAPS podcast introduces listeners to social listening to gather insights and discusses implementation, value and technologies.
This Webinar provides perspectives on the evolving role of Digital Opinion Leaders in medical education and shares approaches for identifying, monitoring and engaging them in a compliant manor with relevant examples.
Part 2 of this series will discuss statistical analysis in clinical trials including null/alternative hypotheses; statistical assumptions (type I error, significance level, type II error, statistical power); hypothesis testing; Statistics used in RCTs, including type of outcome measures, analysis of time-to-event variables (plotting and interpretation of Kaplan-Meier curves).
Early Access includes a variety of programs by which pharmaceutical companies make investigational therapies available to patients with life-threatening diseases. These patients have either exhausted available treatments or have no approved options. This presentation will review the processes and procedures to consider in the implementation of an Early Access Program and explore the opportunities and challenges posed therein.
Understand the numerous ways in which partnership with patients can impact the development and commercialization of medicines; the current “patient centric” landscape in pharmaceutical drug development; recent findings related to the value of patient-centric trial design, and innovative approaches to engaging with patients across the study continuum.
MSLs are becoming more important and playing key roles across the lifecycle in partnership with many others who play important roles. We will describe the landscape, drivers, and opportunities for engaging with customers across the lifecycle and how we socialize learnings across the organization.
Ensure understanding of the basic components and processes involved in the development of a scientific communication platform (SCP); how to develop and/or update an SCP so that the scientific and value narratives are integrated; learn how to train and implement an SCP across functional teams; glean insights into tailoring a global SCP to a regional SCP